At the news
? NEUTRALIMPACT 3/10 SC 13G filed Nov 9, 2026 at 14:24 ET
Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC disclosed a 5.8% passive stake in Sionna Therapeutics via a Schedule 13G filing. The stake of 2,639,418 shares was held as of September 30, 2026, and the filing certifies passive intent with no aim to influence control.
- Goldman Sachs Group and Goldman Sachs & Co. LLC filed a Schedule 13G disclosing beneficial ownership of 2,639,418 shares of Sionna Therapeutics common stock.
- The stake represents 5.8% of shares outstanding as of September 30, 2026.
- The filing certifies the securities were acquired and held in the ordinary course of business, not to change or influence control.
- This is a new 13G filing by Goldman Sachs; no prior 13G from this filer appears in the cross-filing context.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access